Metalyse

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

tenecteplase

Available from:

Boehringer Ingelheim International GmbH

ATC code:

B01AD11

INN (International Name):

tenecteplase

Therapeutic group:

Antitrombotična sredstva

Therapeutic area:

Miokardni infarkt

Therapeutic indications:

Metalyse je indicirano za trombolitična zdravljenje domnevnih miokardnega infarkta z vztrajno ST dviganje ali zadnjih levo-svežnju-podružnica blok v šestih urah po pojavu simptomov akutni miokardni infarkt.

Product summary:

Revision: 22

Authorization status:

Pooblaščeni

Authorization date:

2001-02-23

Patient Information leaflet

                                33
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte pri temperaturi do 30 °C.
Vsebnik shranjujte v zunanji ovojnini za zagotovitev zaščite pred
svetlobo.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
Nemčija
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/00/169/005
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
Podatki, ki morajo biti navedeni na notranji strani pokrova škatle v
obliki piktograma
NAVODILO ZA UPORABO
1 Odpremo zgornji del nastavka za vialo. Snamemo zaporko s konice
brizge. Z viale snamemo
tesnilno zaporko.
2 Napolnjeno brizgo čvrsto privijemo v nastavek za vialo.
3 Zamašek viale v sredini prebodemo s konico nastavka za vialo.
4 Dodamo vodo za injekcije, tako da brizgin bat počasi potisnemo
navzdol, da preprečimo penjenje.
34
5 Injekcijsko brizgo pustimo pritrjeno na vialo in raztopino
rekonstituiramo z rahlim vrtenjem viale in
brizge.
6 Obrnemo vialo/brizgo in prenesemo ustrezen volumen raztopine v
brizgo v skladu z navodili za
odmerjanje.
7 Brizgo odvijemo z nastavka za vialo. Raztopina je sedaj pripravljena
za i.v. bolusno injekcijo.
16.
PODATKI V BRAILLOVI PISAVI
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI
PC
SN
NN
35
PODATKI NA PRIMARNI OVOJNINI
NALEPKA NA VIALI
1.
IME ZDRAVILA
Metalyse 8000 enot (40 mg)
prašek za raztopino za injiciranje
tenekteplaza
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
Ena viala vsebuje 8000 enot (40 mg) tenekteplaze.
Rekonstituirana raztopina vsebuje 1000 enot (5 mg) tenekteplaze v 1
ml.
3.
SEZNAM POMOŽNIH SNOVI
arginin, koncentrirana fosforjeva (V) kislina, polisorbat 20
Ostanek v sledeh iz proizvodnega postopka: gentamicin.
4.
FARMACEVTSKA OBLIKA IN V
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Metalyse 8000 enot (40 mg) prašek in vehikel za raztopino za
injiciranje
Metalyse 10 000 enot (50 mg) prašek in vehikel za raztopino za
injiciranje
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Metalyse 8000 enot (40 mg) prašek in vehikel za raztopino za
injiciranje
Ena viala vsebuje 8000 enot (40 mg) tenekteplaze.
Ena napolnjena injekcijska brizga vsebuje 8 ml vehikla.
Metalyse 10 000 enot (50 mg) prašek in vehikel za raztopino za
injiciranje
Ena viala vsebuje 10 000 enot (50 mg) tenekteplaze.
Ena napolnjena injekcijska brizga vsebuje 10 ml vehikla.
Rekonstituirana raztopina vsebuje 1000 enot (5 mg) tenekteplaze v 1
ml.
Jakost tenekteplaze je izražena v enotah (E), ki so določene s
specifičnim referenčnim standardom za
tenekteplazo in niso primerljive z enotami, ki jih uporabljamo za
druge trombolitike.
Tenekteplaza je za fibrin specifični aktivator plazminogena, izdelan
na liniji ovarijskih celic kitajskega
hrčka s tehnologijo rekombinantne DNA.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
Prašek in vehikel za raztopino za injiciranje.
Prašek je bele do skoraj bele barve.
Vehikel je prozoren in brezbarven.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo Metalyse je pri odraslih indicirano za trombolitično
zdravljenje pri sumu na miokardni
infarkt s persistentno elevacijo spojnice ST ali nedavnim levokračnim
blokom, v 6 urah po pojavu
simptomov akutnega miokardnega infarkta.
4.2
ODMERJANJE IN NAČIN UPORABE
Odmerjanje
Zdravilo Metalyse morajo predpisati zdravniki, ki imajo izkušnje s
trombolitičnim zdravljenjem in na
voljo opremo za njegovo spremljanje.
Zdravljenje z zdravilom Metalyse moramo začeti čim prej po pojavu
simptomov.
Ustrezen odmerek tenekteplaze je treba izbrati skrbno in v skladu z
indikacijo. Odmerka po 40 mg in
50 mg sta namenjena samo za uporabo pri akutnem miokardnem infarktu.
3
Odmerjanje zdravila Metalyse določimo glede na telesno maso.
Največji odmerek je 10 000 enot
(50 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 02-04-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 02-04-2024
Public Assessment Report Public Assessment Report Bulgarian 29-07-2014
Patient Information leaflet Patient Information leaflet Spanish 02-04-2024
Public Assessment Report Public Assessment Report Spanish 29-07-2014
Patient Information leaflet Patient Information leaflet Czech 02-04-2024
Public Assessment Report Public Assessment Report Czech 29-07-2014
Patient Information leaflet Patient Information leaflet Danish 02-04-2024
Public Assessment Report Public Assessment Report Danish 29-07-2014
Patient Information leaflet Patient Information leaflet German 02-04-2024
Public Assessment Report Public Assessment Report German 29-07-2014
Patient Information leaflet Patient Information leaflet Estonian 02-04-2024
Public Assessment Report Public Assessment Report Estonian 29-07-2014
Patient Information leaflet Patient Information leaflet Greek 02-04-2024
Public Assessment Report Public Assessment Report Greek 29-07-2014
Patient Information leaflet Patient Information leaflet English 02-04-2024
Public Assessment Report Public Assessment Report English 29-07-2014
Patient Information leaflet Patient Information leaflet French 02-04-2024
Public Assessment Report Public Assessment Report French 29-07-2014
Patient Information leaflet Patient Information leaflet Italian 02-04-2024
Public Assessment Report Public Assessment Report Italian 29-07-2014
Patient Information leaflet Patient Information leaflet Latvian 02-04-2024
Public Assessment Report Public Assessment Report Latvian 29-07-2014
Patient Information leaflet Patient Information leaflet Lithuanian 02-04-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 02-04-2024
Public Assessment Report Public Assessment Report Lithuanian 29-07-2014
Patient Information leaflet Patient Information leaflet Hungarian 02-04-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 02-04-2024
Public Assessment Report Public Assessment Report Hungarian 29-07-2014
Patient Information leaflet Patient Information leaflet Maltese 02-04-2024
Public Assessment Report Public Assessment Report Maltese 29-07-2014
Patient Information leaflet Patient Information leaflet Dutch 02-04-2024
Public Assessment Report Public Assessment Report Dutch 29-07-2014
Patient Information leaflet Patient Information leaflet Polish 02-04-2024
Public Assessment Report Public Assessment Report Polish 29-07-2014
Patient Information leaflet Patient Information leaflet Portuguese 02-04-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 02-04-2024
Public Assessment Report Public Assessment Report Portuguese 29-07-2014
Patient Information leaflet Patient Information leaflet Romanian 02-04-2024
Public Assessment Report Public Assessment Report Romanian 29-07-2014
Patient Information leaflet Patient Information leaflet Slovak 02-04-2024
Public Assessment Report Public Assessment Report Slovak 29-07-2014
Patient Information leaflet Patient Information leaflet Finnish 02-04-2024
Public Assessment Report Public Assessment Report Finnish 29-07-2014
Patient Information leaflet Patient Information leaflet Swedish 02-04-2024
Public Assessment Report Public Assessment Report Swedish 29-07-2014
Patient Information leaflet Patient Information leaflet Norwegian 02-04-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 02-04-2024
Patient Information leaflet Patient Information leaflet Icelandic 02-04-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 02-04-2024
Patient Information leaflet Patient Information leaflet Croatian 02-04-2024
Public Assessment Report Public Assessment Report Croatian 29-07-2014

Search alerts related to this product

View documents history